L
15.24
-1.05 (-6.45%)
| 前收盘价格 | 16.29 |
| 收盘价格 | 16.35 |
| 成交量 | 2,146,906 |
| 平均成交量 (3个月) | 1,216,314 |
| 市值 | 476,859,104 |
| 价格/销量 (P/S) | 26.02 |
| 股市价格/股市净资产 (P/B) | 2.63 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 稀释每股收益 (EPS TTM) | 0.660 |
| 总债务/股东权益 (D/E MRQ) | 0.62% |
| 流动比率 (MRQ) | 23.09 |
| 营业现金流 (OCF TTM) | -51.50 M |
| 杠杆自由现金流 (LFCF TTM) | -40.56 M |
| 资产报酬率 (ROA TTM) | -17.75% |
| 股东权益报酬率 (ROE TTM) | -24.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | LENZ Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.38 |
|
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 2.76% |
| 机构持股比例 | 92.94% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ra Capital Management, L.P. | 30 Sep 2025 | 4,178,823 |
| Alpha Wave Global, Lp | 30 Sep 2025 | 3,612,211 |
| Versant Venture Management, Llc | 30 Sep 2025 | 2,656,888 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 1,073,461 |
| 72 Investment Holdings, Llc | 30 Sep 2025 | 1,017,751 |
| Rtw Investments, Lp | 30 Sep 2025 | 863,389 |
| First Light Asset Management, Llc | 30 Sep 2025 | 693,044 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 67.00 (Piper Sandler, 339.63%) | 购买 |
| 中 | 58.50 (283.86%) | |
| 低 | 50.00 (Raymond James, 228.08%) | 购买 |
| 平均值 | 58.50 (283.86%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 37.55 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Raymond James | 20 Oct 2025 | 50.00 (228.08%) | 购买 | 36.31 |
| Piper Sandler | 10 Oct 2025 | 67.00 (339.63%) | 购买 | 38.79 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合